越来越多的证据表明，癌症患者接受治疗的时间可能会影响他们的治疗效果。这种影响可能与免疫细胞功能以及调节其功能的蛋白（也称为检查点）的昼夜节律波动有关。一项最新的荟萃分析显示，接受免疫检查点抑制剂（Immune Checkpoint Inhibitor, ICI）输注治疗的多种晚期癌症患者，在上午接受治疗的患者比在下午或晚上接受治疗的患者存活时间更长。（参考文献：Landré T, et al.

Giving immunotherapy earlier in the day can significantly extend patients' survival, compared to giving treatment later in ...

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival.

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

The FLAURA2 trial showed that combining Tagrisso with chemotherapy improved survival in EGFR-mutated NSCLC, especially in patients with liver metastases and TP53 alterations. Addressing emotional and ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.